[1] Duncan, R., Polymer therapeutics: Top 10 selling pharmaceuticals — What next? Journal of Controlled Release, 2014. 190(Supplement C): p. 371-380.
[2] Pasut, G., Polymers for Protein Conjugation. Polymers, 2014. 6(1): p. 160.
[3] Harari, D., et al., Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis. The Journal of biological chemistry, 2014. 289(42): p. 29014-29029.
[4] Leader, B., Q.J. Baca, and D.E. Golan, Protein therapeutics: a summary and pharmacological classification. Nature reviews. Drug discovery, 2008. 7(1): p. 21.
[5] Abuchowski, A., et al., Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. Journal of Biological Chemistry, 1977. 252(11): p. 3582-6.
[6] Caliceti, P. and F.M. Veronese, Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates. Advanced Drug Delivery Reviews, 2003. 55(10): p. 1261-1277.
[7] Webster, R., et al., PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals. PEGylated protein drugs: Basic science and clinical applications, 2009: p. 127-146.
[8] Harris, J.M. and R.B. Chess, Effect of pegylation on pharmaceuticals. Nature reviews. Drug discovery, 2003. 2(3): p. 214.
[9] Bailon, P., et al., Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C. Bioconjugate chemistry, 2001. 12(2): p. 195-202.
[10] Schlapschy, M., et al., PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins. Protein Engineering, Design & Selection, 2013. 26(8): p. 489-501.
[11] Veronese, F.M. and G. Pasut, PEGylation, successful approach to drug delivery. Drug discovery today, 2005. 10(21): p. 1451-1458.
[12] Gabizon, A., et al., Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid–PEG conjugates. Advanced drug delivery reviews, 2004. 56(8): p. 1177-1192.
[13] Garay, R.P., et al., Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. 2012, Taylor & Francis.
[14] Greenwald, R.B., et al., Effective drug delivery by PEGylated drug conjugates. Advanced drug delivery reviews, 2003. 55(2): p. 217-250.
[15] Patri, A.K., J.F. Kukowska-Latallo, and J.R. Baker, Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Advanced drug delivery reviews, 2005. 57(15): p. 2203-2214.
[16] Knop, K., et al., Poly (ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angewandte Chemie International Edition, 2010. 49(36): p. 6288-6308.
[17] Carlson, H.A. and J.A. McCammon, Accommodating protein flexibility in computational drug design. Molecular pharmacology, 2000. 57(2): p. 213-218.
[18] Lill, M.A. and M.L. Danielson, Computer-aided drug design platform using PyMOL. Journal of computer-aided molecular design, 2011. 25(1): p. 13-19.
[19] Yang, C., D. Lu, and Z. Liu, How PEGylation enhances the stability and potency of insulin: a molecular dynamics simulation. Biochemistry, 2011. 50(13): p. 2585-2593.
[20] Yang, H. and A.H. Elcock, Association lifetimes of hydrophobic amino acid pairs measured directly from molecular dynamics simulations. Journal of the American Chemical Society, 2003. 125(46): p. 13968-13969.
[21] Eun, C., Molecular dynamics simulations study of hydrophilic and hydrophobic interactions between nanoscale particles. 2010.
[22] Maiti, M., et al., Potential of mean force between hydrophobic solutes in the Jagla model of water and implications for cold denaturation of proteins. The Journal of chemical physics, 2012. 136(4): p. 044512.
[23] Samanta, U., R.P. Bahadur, and P. Chakrabarti, Quantifying the accessible surface area of protein residues in their local environment. Protein engineering, 2002. 15(8): p. 659-667.
[24] Moelbert, S., E. Emberly, and C. Tang, Correlation between sequence hydrophobicity and surface‐exposure pattern of database proteins. Protein Science, 2004. 13(3): p. 752-762.
[25] Moret, M. and G. Zebende, Amino acid hydrophobicity and accessible surface area. Physical Review E, 2007. 75(1): p. 011920.
[26] Aritomi, M., et al., Atomic structure of the GCSF-receptor complex showing a new cytokine-receptor recognition scheme. Nature, 1999. 401(6754): p. 713.